Danaher sees Q4 EPS above high end of 80c-85c range, consensus 83c Sees higher than expected core revenue growth in Q4, consensus $4.47B. Company says CEO H. Lawrence Culp to comment on results at JPMorgan Healthcare Conference January 9.
Danaher price target raised to $100 from $89 at Jefferies Jefferies raised its price target for Danaher shares to $100 ahead of the company's investor day and keeps a Buy rating on the name. It expects an initial 2015 organic growth outlook of 3% and earnings guidance of $3.95 and ex-amortization $4.40. Jefferies keeps a Buy rating on the stock.